Boston Children's Hospital and Life Technologies Launch Claritas Genomics, a Clinical Genomics Company
News Jan 10, 2013
Boston Children's Hospital has partnered with Life Technologies Corporation to launch Claritas Genomics, a new company formed to develop next-generation, genetic and genomics-based diagnostic testing solutions. The venture combines advanced instrumentation, software and bioinformatics capabilities with sophisticated clinical interpretation of test results and consultation by specialist physicians and medical genomics experts at Boston Children's Hospital.
Claritas Genomics, majority-owned by Children's, will incorporate the expertise, assets and personnel of the hospital's Genetic Diagnostic Lab, a CLIA-certified center that already offers more than 100 genetic tests, including many specialized diagnostics developed at Boston Children's. It will leverage Life Technologies' Ion Proton® Sequencer, a fast, accurate benchtop technology that can readily be scaled for mass application for new tests that the company plans to develop.
"While a number of academic and private ventures are offering genomic sequencing and molecular diagnostics to the public, no other partnership has integrated all the elements—fast, accurate genomic sequencing, bioinformatics, CLIA expertise and access to researchers and clinicians who can interpret the data in a meaningful way," said Sandra Fenwick, president and chief operating officer of Boston Children's. "We want to advance the standard of care, create a seamless experience and extend it to children and adults across the U.S. and around the world."
"Our investment in Claritas Genomics is a prime example of strategic partnerships Life Technologies is entering into to accelerate the use of accurate genomic information in medical practice," said Greg Lucier, chairman and chief executive officer of Life Technologies. "This new venture serves as a model for future endeavors to demonstrate the validation of our Ion Torrent technology in an integrated laboratory workflow designed for clinical applications related to pediatrics and inherited diseases."
Claritas Genomics will seek to validate the Ion Proton® Sequencer's clinical utility and tests developed on the platform for clinical use. For Boston Children's Hospital, a leader in applying knowledge about genomic variation for patient care and basic research, the formation of the company is a strategic opportunity to assure its physicians and scientists access to best-in-world genomic science and to share its expertise in genomic interpretation widely.
"Boston Children's has already invested significantly to accelerate genomic discovery for patients with rare diseases, cancer and autism, and to profile individual responses to medications. We now have a practical paradigm for taking genetic and genomic research discoveries to the bedside, and we're excited to be able to scale up and offer this capability to patients everywhere," said David Margulies, MD, executive director of the Gene Partnership at Boston Children's Hospital. "Through a set of network collaborations and via electronic communications, we plan to provide interpretive services around the world."
The new company is developing relationships with other U.S. and international children's hospitals to create a network of top-tier pediatric academic centers that can share data, especially important for rare diseases that require large numbers of patients to discover genetic markers.
Ion Proton® Sequencer is for research use only, not for use in diagnostic procedures.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018